Empagliflozin (SGLT2 Inhibitor)
Treatment for Diabetes Mellitus Type 2
Typical Dosage: 10-25 mg daily
Effectiveness
89%
Safety Score
60%
Clinical Trials
69
Participants
80K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
10-25 mg daily
Time to Effect
Days to 1-2 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$9,000
Monitoring:$450
Side Effect Mgmt:$150
Total Annual:$9,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$13,333.33
Cost per Remission
$160,000
Comparison vs Sitagliptin
Cost Difference
+$4,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Empagliflozin (SGLT2 Inhibitor) Outcomes
for Diabetes Mellitus Type 2
Efficacy Outcomes
Overall Effectiveness
+89%
Response Rate
+72%
Remission Rate
+6%
Common Side Effects
Genital mycotic infections
+7%
Urinary tract infections
+4%
Polyuria
+4%
Volume depletion/hypotension
+1.5%
Diabetic ketoacidosis (euglycemic DKA)
+0.1%
Sources:
Active Clinical Trials
5 active trials recruiting for Empagliflozin (SGLT2 Inhibitor) in Diabetes Mellitus Type 2
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
NCT05770687RECRUITING
1K participants
OBSERVATIONAL
Seoul, South Korea
Started: Aug 1, 2020
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
NCT05029115ENROLLING BY INVITATION
716 participants
OBSERVATIONAL
Yangcheon, South Korea
Started: Oct 5, 2021
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
NCT07325435ACTIVE NOT RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Brooklyn, United States
Started: Dec 21, 2024
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
NCT07198191ACTIVE NOT RECRUITING
200K participants
OBSERVATIONAL
Yongin, South Korea
Started: Sep 1, 2014
SGLTi, Hepatic Glucose Production and Ketogenesis
NCT05960656RECRUITINGPHASE1
30 participants
INTERVENTIONAL
San Antonio, United States
Started: Oct 5, 2023
Completed Clinical Trials
11 completed trials for Empagliflozin (SGLT2 Inhibitor) in Diabetes Mellitus Type 2
Performance Under SGLT-2-Inhibitors in Humans
NCT03422263COMPLETED
450 participants
OBSERVATIONAL
Crans-Montana, Switzerland
Started: Jan 1, 2018
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
NCT04184947COMPLETED
10K participants
OBSERVATIONAL
Padua, Italy
Started: Mar 1, 2014
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
NCT07269197COMPLETED
67 participants
OBSERVATIONAL
Osijek, Croatia
Started: Mar 22, 2024
Impact of SGLT2 on Glucosuria in HNF1A-MODY
NCT05417646COMPLETEDNA
21 participants
INTERVENTIONAL
Herlev, Denmark
Started: Jun 22, 2022
SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
NCT04735042COMPLETED
60 participants
OBSERVATIONAL
Pisa, Italy
Started: Oct 7, 2020
Characteristics of Empagliflozin Initiators
NCT03050619COMPLETED
31.9K participants
OBSERVATIONAL
Ingelheim, Germany
Started: Sep 10, 2016
Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes
NCT06797115COMPLETED
40 participants
OBSERVATIONAL
Pécs, Hungary
Started: Jul 18, 2022
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
NCT03226457COMPLETEDPHASE4
23 participants
INTERVENTIONAL
Dundee, United Kingdom
Started: Dec 11, 2017
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
NCT05359341COMPLETEDNA
175 participants
INTERVENTIONAL
El Sadat, Egypt
Started: Sep 20, 2020
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
NCT03817463COMPLETED
328K participants
OBSERVATIONAL
Gentofte Municipality, Denmark +12 more
Started: Apr 15, 2019
Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents
NCT02636192COMPLETED
200K participants
OBSERVATIONAL
Started: Jul 31, 2015
Showing 20 of 73 total trials